Related Experiment Video
Updated: May 30, 2025
02:28
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
328
Cross-sectional study of proteomic differences between moderate and severe psoriasis.
Lingling Wu1, Chen Cen1, Bibo Xie1
1Department of Dermatology, Dermatology Hospital of Zhejiang Province, Huzhou, 313299, China.
Scientific Reports
|January 27, 2025
Summary
Proteomic analysis revealed significant differences between moderate and severe psoriasis. Key proteins linked to inflammation and immune response pathways may serve as biomarkers for disease severity.
Area of Science:
- Proteomics
- Immunology
- Dermatology
Background:
- Psoriasis vulgaris (PV) pathogenesis is not fully understood, particularly the proteomic distinctions between moderate and severe forms.
- Identifying these differences is crucial for understanding disease progression and developing targeted therapies.
Purpose of the Study:
- To investigate the proteomic profiles of moderate versus severe psoriasis vulgaris.
- To identify differentially expressed proteins (DEPs) and associated pathways that correlate with disease severity.
Main Methods:
- Cross-sectional study utilizing data-independent acquisition mass spectrometry (DIA-MS) to compare protein expression in moderate and severe psoriasis.
- Ingenuity Pathway Analysis (IPA) and 4D-parallel reaction monitoring (4D-PRM) were employed for further analysis.
Main Results:
- 173 DEPs were identified (85 upregulated, 88 downregulated) between moderate and severe psoriasis.
- Eighteen DEPs were significantly enriched in pathways including IL-17 signaling, Neutrophil extracellular trap formation, Neutrophil degranulation, and NF-κB signaling.
- TNF and TDP53 were identified as top upstream up-regulators, while Lipopolysaccharide and YAP1 were potential down-regulators.
Conclusions:
- The study identified 18 DEPs as potential biomarkers for psoriasis severity, linked to key inflammatory and immune response pathways.
- Targeting these identified proteins and managing associated infections could potentially improve psoriasis severity and treatment outcomes.
